Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says

UBS initiated coverage on Harmony Biosciences Holdings Inc HRMY, a commercial-stage biopharmaceutical company focused on rare neurological disorders. The company's marketed medicine, Wakix (pitolisant), is approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. Wakix generated net revenues of $172.8 million in the second quarter of 2024, up 29% year-over-year. The average number of patients on Wakix increased by approximately 250 patients sequentially to approximately 6,550 ...